瑞戈非尼
生产厂家：东盟（老挝）制药与食品有限公司
功能主治：用于多种实体瘤，二线治疗肝癌中位生存显著延长
用法用量：用法用量 (1).28天为一个周期，每个周期的前21天，每天一次性口服160毫克。 持续治疗直到出现疾病进展或不可耐受的药物毒性。 (2).每天在同一时间点服药，用药前用低脂餐(热量少于60卡路里，脂肪少于30%)。 不要在同一天服用两天的剂量。
查看详情
Regorafenib belongs to a class of drugs known as multi-kinase inhibitors. It works by inhibiting the growth of blood vessels that supply the tumor, thereby starving the cancer cells and preventing the spread of the disease. In addition, it also blocks proteins involved in tumor growth, reducing the chances of cancer progression.
Clinical trials have shown remarkable results in the efficacy of Regorafenib in the treatment of advanced liver cancer. In a study conducted on patients who had exhausted all other treatment options, Regorafenib was found to increase overall survival rates significantly. Patients who received Regorafenib lived longer compared to those who received a placebo, with fewer side effects.
One of the advantages of Regorafenib is its oral administration. Unlike traditional chemotherapy, which often requires intravenous delivery, this drug can be conveniently taken as a pill, allowing patients to receive treatment in the comfort of their own homes. This convenience not only improves patients' quality of life but also increases compliance with the treatment regimen, which is crucial for the drug's effectiveness.
Like any medication, Regorafenib has potential side effects. Common side effects include fatigue, hand-foot syndrome, gastrointestinal discomfort, and hypertension. However, these can be managed with appropriate medical intervention and support from healthcare professionals. The benefits of Regorafenib in terms of survival outweigh its potential side effects, making it a promising option for liver cancer patients.
In addition to its efficacy in liver cancer, Regorafenib is now being studied for its potential in other types of cancer as well. Clinical trials are underway to determine its effectiveness in colorectal cancer, gastrointestinal stromal tumors, and other solid tumors. This highlights the versatility of Regorafenib as a treatment option and its potential to transform the landscape of cancer treatments in the future.
Despite its remarkable success, Regorafenib is still not accessible to all liver cancer patients due to its high cost. It remains an expensive drug, making it challenging for many individuals to afford. However, with ongoing research and potential generic versions in the future, it is hoped that the availability of Regorafenib will increase, providing more patients with a chance at life.
In conclusion, Regorafenib is a breakthrough drug that has revolutionized the treatment of liver cancer. Its ability to inhibit tumor growth and increase survival rates offers new hope to patients who have exhausted all other treatment options. With further research and potential cost reductions, more patients can benefit from the life-saving effects of Regorafenib. This drug represents a significant milestone in the field of cancer treatment, paving the way for new and improved therapies in the future.
